EFFICACY AND SAFETY OF SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO LBEC0101 (ETANERCEPT BIOSIMILAR) COMPARED WITH CONTINUING LBEC0101 IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：3
|
作者：
Song, Y. W. [1 ]
Matsuno, H. [2 ,3 ]
Park, M. -C. [4 ]
Tomomitsu, M. [5 ]
Shin, S. [6 ]
Lee, J. [6 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
[2] Tokyo Med Univ, Tokyo, Japan
[3] Matsuno Clin Rheumat Dis, Toyama, Japan
[4] Yonsei Univ, Div Rheumatol, Coll Med, Seoul, South Korea
[5] Mochida Pharmaceut Co Ltd, Tokyo, Japan
[6] LG CHEM, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1316
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0456
引用
收藏
页码：1389 / 1390
页数：3
相关论文
共 50 条
  • [41] Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
    Mark C. Genovese
    Juan Sanchez-Burson
    MyungShin Oh
    Eva Balazs
    Jeffrey Neal
    Andrea Everding
    Tomas Hala
    Rafal Wojciechowski
    Gary Fanjiang
    Stanley Cohen
    Arthritis Research & Therapy, 22
  • [42] Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
    Genovese, Mark C.
    Sanchez-Burson, Juan
    Oh, MyungShin
    Balazs, Eva
    Neal, Jeffrey
    Everding, Andrea
    Hala, Tomas
    Wojciechowski, Rafal
    Fanjiang, Gary
    Cohen, Stanley
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [43] Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry
    Horneff, G.
    De Bock, F.
    Foeldvari, I.
    Girschick, H. J.
    Michels, H.
    Moebius, D.
    Schmeling, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) : 519 - 525
  • [44] Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
    Koike, Takao
    Harigai, Masayoshi
    Inokuma, Shigeko
    Ishiguro, Naoki
    Ryu, Junnosuke
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Yamanaka, Hisashi
    Fujii, Koichi
    Yoshinaga, Takunari
    Freundlich, Bruce
    Suzukawa, Michio
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (06) : 1617 - 1624
  • [45] Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study
    Takao Koike
    Masayoshi Harigai
    Shigeko Inokuma
    Naoki Ishiguro
    Junnosuke Ryu
    Tsutomu Takeuchi
    Yoshiya Tanaka
    Hisashi Yamanaka
    Koichi Fujii
    Takunari Yoshinaga
    Bruce Freundlich
    Michio Suzukawa
    Rheumatology International, 2012, 32 : 1617 - 1624
  • [46] Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
    Kavanaugh, Arthur
    Matucci-Cerinic, Marco
    Schulze-Koops, Hendrik
    Buch, Maya
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [47] SWITCHING FROM REFERENCE PRODUCT ETANERCEPT TO THE BIOSIMILAR SB4 IN A REAL-LIFE SETTING: FOLLOW-UP OF 147 PATIENTS
    Sigurdardottir, V.
    Husmark, T.
    Svard, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 835 - 835
  • [48] IMPACT OF ANTI-DRUG ANTIBODY AND INJECTION SITE REACTION ON EFFICACY: 24-WEEK RESULTS FROM A PHASE III STUDY COMPARING SB4 (ETANERCEPT BIOSIMILAR) WITH REFERENCE ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Vencovsky, J.
    Emery, P.
    Keystone, E.
    Ghil, J.
    Cheong, S. Y.
    Hong, E. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 137 - 137
  • [49] Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis
    Vencovsky, Jiri
    Emery, Paul
    Keystone, Edward C.
    Ghil, Jeehoon
    Cheong, Soo Yeon
    Hong, Evelyn
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [50] Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study
    Sakane, Hideo
    Yonemoto, Yukio
    Okamura, Koichi
    Suto, Takahito
    Inoue, Makoto
    Mitomi, Hirofumi
    Tsuchida, Kosei
    Kaneko, Tetsuya
    Tamura, Yasuyuki
    Chikuda, Hirotaka
    JOURNAL OF ORTHOPAEDIC SURGERY, 2024, 32 (02)
12345